scispace - formally typeset
H

Hywel David Williams

Researcher at Monash University

Publications -  45
Citations -  3410

Hywel David Williams is an academic researcher from Monash University. The author has contributed to research in topics: Solubility & Bioavailability. The author has an hindex of 24, co-authored 44 publications receiving 2851 citations. Previous affiliations of Hywel David Williams include Capsugel & Monash University, Parkville campus.

Papers
More filters
Journal ArticleDOI

Digestion of Phospholipids after Secretion of Bile into the Duodenum Changes the Phase Behavior of Bile Components

TL;DR: It is suggested that mixtures of lysolecithin, fatty acid, and bile salts are a better model of molecular associations in the gut lumen, and such mixtures could be used to better understand the interaction of drugs with the fat digestion and absorption pathway.
Journal ArticleDOI

Unlocking the full potential of lipid-based formulations using lipophilic salt/ionic liquid forms.

TL;DR: A new lipophilic salt / ionic liquid approach in combination with LBF is described, and how this salt strategy can be used to better tailor the properties of a drug to LBFs to meet the demands of modern drugs.
Journal ArticleDOI

In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.

TL;DR: Replacing LC lipids with MC lipids in Type II and IIIA LBF, in the proportions used here has little effect on fenofibrate solubilization during dispersion, but is likely to promote supersaturation on digestion.
Journal ArticleDOI

An in Vitro Digestion Test That Reflects Rat Intestinal Conditions To Probe the Importance of Formulation Digestion vs First Pass Metabolism in Danazol Bioavailability from Lipid Based Formulations

TL;DR: In vitro digestion models based on likely rat GI conditions suggest less drug precipitation on formulation digestion when compared to equivalent dog models, consistent with the increases in in vivo exposure (fraction absorbed) seen here in ABT-pretreated rats.
Journal ArticleDOI

Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations.

TL;DR: Application of a lipophilic salt approach can facilitate the use of lipid-based formulations for examples of the smKI compound class where low solubility limits absorption and is a risk factor for increased variability due to food-effects.